Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Rudick

Showing results (41-50 of 188) with videos related to

Pageof 19
Sort By:
Scandinavian Journal of Immunology|January 1, 1985
Isolation of model soluble immune complexes in the fluid phase by monoclonal anti-IgG-ferritin antibodiesD W Knutson, R A Rudick, R M Herndon
Therapeutic Advances in Neurological Disorders|December 24, 2010
Possible clinical outcome measures for clinical trials in patients with multiple sclerosisMyla D Goldman, Robert W Motl, Richard A Rudick
Annals of Neurology|June 21, 2006
Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal studyRichard A Rudick, Jar-Chi Lee, Jack Simon, et al.
Current Opinion in Neurology|June 1, 1994
Advances in specific therapy for multiple sclerosisL Jacobs, D E Goodkin, R A Rudick, et al.
Annals of Neurology|July 29, 2008
Gray matter atrophy in multiple sclerosis: a longitudinal studyElizabeth Fisher, Jar-Chi Lee, Kunio Nakamura, et al.
Journal of the Neurological Sciences|December 23, 2008
Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSSRichard A Rudick, Jar-Chi Lee, Kunio Nakamura, et al.
Neurology|December 17, 2013
Assessing treatment response to interferon-β: is there a role for MRI?Ruth Dobson, Richard A Rudick, Ben Turner, et al.
Nutricion Hospitalaria|January 1, 1995
[Fat-rich diets in patients with mild chronic obstructive lung disease (COPD)]M Planas, J Raskin, A Rudick, et al.
Annals of Neurology|September 1, 2005
Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutationIlka Warshawsky, Richard A Rudick, Susan M Staugaitis, et al.
Neuroepidemiology|June 17, 2010
Validation of a self-report comorbidity questionnaire for multiple sclerosisMyles Horton, Richard A Rudick, Claire Hara-Cleaver, et al.
Pageof 19

Showing results (41-50 of 188) with videos related to

Sort By:
Pageof 19
Scandinavian Journal of Immunology|January 1, 1985
Isolation of model soluble immune complexes in the fluid phase by monoclonal anti-IgG-ferritin antibodiesD W Knutson, R A Rudick, R M Herndon
Therapeutic Advances in Neurological Disorders|December 24, 2010
Possible clinical outcome measures for clinical trials in patients with multiple sclerosisMyla D Goldman, Robert W Motl, Richard A Rudick
Annals of Neurology|June 21, 2006
Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal studyRichard A Rudick, Jar-Chi Lee, Jack Simon, et al.
Current Opinion in Neurology|June 1, 1994
Advances in specific therapy for multiple sclerosisL Jacobs, D E Goodkin, R A Rudick, et al.
Annals of Neurology|July 29, 2008
Gray matter atrophy in multiple sclerosis: a longitudinal studyElizabeth Fisher, Jar-Chi Lee, Kunio Nakamura, et al.
Journal of the Neurological Sciences|December 23, 2008
Gray matter atrophy correlates with MS disability progression measured with MSFC but not EDSSRichard A Rudick, Jar-Chi Lee, Kunio Nakamura, et al.
Neurology|December 17, 2013
Assessing treatment response to interferon-β: is there a role for MRI?Ruth Dobson, Richard A Rudick, Ben Turner, et al.
Nutricion Hospitalaria|January 1, 1995
[Fat-rich diets in patients with mild chronic obstructive lung disease (COPD)]M Planas, J Raskin, A Rudick, et al.
Annals of Neurology|September 1, 2005
Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutationIlka Warshawsky, Richard A Rudick, Susan M Staugaitis, et al.
Neuroepidemiology|June 17, 2010
Validation of a self-report comorbidity questionnaire for multiple sclerosisMyles Horton, Richard A Rudick, Claire Hara-Cleaver, et al.
Pageof 19